Department of Radiology, University of Cambridge School of Clinical Medicine.
E-mail: Marta Wylot
Marta Wylot is a member of multidisciplinary Hyperpolariser research group and she coordinates and manages multiple ongoing clinical research studies as well as awarded research income. She is involved in the development of new imaging probes as part of single centre and multi-centre studies and is an active member in the Clinical Trials Unit (CTU) for the National Cancer Imaging Translational Accelerator (NCTIA).
Prior to joining the Department of Radiology, Marta was a gene therapy clinical trial coordinator for Prof Robert Maclaren at Oxford University Hospitals and was responsible for conducting projects sponsored by Biogen and Novartis. She gained experience in non-interventional studies while working for Adelphi Real World. During the COVID-19 pandemic she put science skills to new use by supporting UK national effort to boost COVID-19 testing, first at the University’s Anne McLaren Building on the Cambridge Biomedical Campus, then at Excalibur Healthcare Services.
Marta earned a first class degree in Medicinal Chemistry from University of Aberdeen. She participated in an ERASMUS research placement at Institut Européen de Chimie et Biologie in Bordeaux, France. She took part in AstraZeneca Graduate Program before starting her industrial CASE PhD in Biochemistry at University of Cambridge. For her PhD project in Prof Jules Griffin group, Marta researched NMR-based methods for monitoring oncology drug treatments in intact cells. In collaboration with Astra Zeneca, she applied a multidisciplinary approach to understand drug-induced changes in intact cells.